Back to Search
Start Over
ADS024, a single-strain live biotherapeutic product of Bacillus velezensis alleviates dextran sulfate-mediated colitis in mice, protects human colonic epithelial cells against apoptosis, and maintains epithelial barrier function.
- Source :
-
Frontiers in microbiology [Front Microbiol] 2024 Jan 10; Vol. 14, pp. 1284083. Date of Electronic Publication: 2024 Jan 10 (Print Publication: 2023). - Publication Year :
- 2024
-
Abstract
- Epithelial cell apoptosis and compromised gut barrier function are features of inflammatory bowel disease. ADS024 is a single-strain live biotherapeutic product (LBP) of Bacillus velezensis under development for treating ulcerative colitis (UC). The cytoprotective effects of the sterile filtrate of ADS024's secreted products on UC patient-derived colonic tissues, human primary colonic epithelial cells (HPEC), and human colonic epithelial T84 cells were evaluated. ADS024 filtrate significantly inhibited apoptosis and inflammation with reduced Bcl-2 Associated X-protein (BAX) and tumor necrosis factor (TNF) mRNA expression in fresh colonic explants from UC patients. Exposure to UC patient-derived serum exosomes (UCSE) induced apoptosis with increased cleaved caspase 3 protein expression in HPECs. ADS024 filtrate diminished the UCSE-mediated apoptosis by inhibiting cleaved caspase 3. TNFα and interferon-gamma (IFNγ) damaged epithelial barrier integrity with reduced transepithelial electrical resistance (TEER). ADS024 filtrate partially attenuated the TEER reduction and restored tight junction protein 1 (TJP1) expression. Oral live ADS024 treatment reduced weight loss, disease activity, colonic mucosal injury, and colonic expression of interleukin 6 (IL-6) and TNFα in dextran sodium sulfate (DSS)-treated mice with colitis. Thus, ADS024 may protect the colonic epithelial barrier in UC via anti-inflammatory, anti-apoptotic, and tight-junction protection mechanisms.<br />Competing Interests: Adiso Therapeutics sponsored this study and a part of HK’s salary. LC and SA are employees of Adiso Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2024 Irwin, Chupina Estrada, Nelson, Bullock, Limketkai, Ho, Acton, Chesnel and Koon.)
Details
- Language :
- English
- ISSN :
- 1664-302X
- Volume :
- 14
- Database :
- MEDLINE
- Journal :
- Frontiers in microbiology
- Publication Type :
- Academic Journal
- Accession number :
- 38268707
- Full Text :
- https://doi.org/10.3389/fmicb.2023.1284083